Find out more about our Academic Medical Centre and efforts in Academic Medicine
Academic Medicine Executive Committee (AM EXCO)
Find out more about what JOAM do to support AM initiatives
Find out more about the Office of Duke-NUS Affairs and Study Trip to Duke Durham
Guidelines, forms, and templates for Academic Medicine.
Clinician scientists and scientists from the National Cancer Centre Singapore (NCCS) have found that epigenomics (changes in the way genes are switched on and off without changing the actual DNA sequence), may be the driving factor behind the development of the primary liver cancer, hepatocellular carcinoma (HCC). This discovery will help in the development of liver cancer treatment strategies in the future, as it supports using systemic and holistic approaches that evaluate tumours and their surrounding cellular environment. The novel findings were published in the journal JHEP Reports late last month.
The epigenome is fast becoming an important field of study in medical research. The epigenome, made up of chemical compounds and proteins that direct the genome, can provide clues into what drives genetic changes that cause cancer. HCC is highly heterogeneous and to date has no validated genetic biomarkers for therapeutic intervention. This makes it difficult to identify effective therapeutics for the disease. Studying the epigenome may be a potentially valuable way to shed light on how genetic changes drive HCC formation.
A research team from the National Cancer Centre Singapore (NCCS) analysed tumour samples from 30 patients with HCC using cutting-edge epigenomics technologies. Taking an orthogonal approach, which uses multiple analytical approaches to arrive at a conclusion, the team employed single cell RNA sequencing and bulk transcriptomics to validate epigenetic changes and study the surrounding cellular environment in depth.
Most significantly, the team were able to confirm that DNA mutations were not in fact major drivers of disease progression in HCC. Instead, they observed that patients with epigenetic changes that caused upregulation of specific signature genes showed a worse prognosis than those without those changes. Their results suggest that the epigenetics changes driven by
metabolic changes in the tumour microenvironment were the driving factors of dysregulation in HCC. Moreover, the results also suggest that oncofoetal reprogramming in HCC, which was a novel immunosuppressive phenomenon reported by the same group previously, was underpinned by genome-wide enhancer rewiring.
“Our findings confirm that genetic changes in the DNA are not major drivers of liver cancer dysregulation, which may explain why, historically, we have not been able to identify genetic predictive biomarkers for hepatocellular carcinoma,” said senior author Professor Pierce Chow, Senior Consultant, Department of Hepato-Pancreato-Biliary and Transplant Surgery, Division of Surgery and Surgical Oncology, Singapore General Hospital and NCCS, and Vice Chair for Research for the Surgery Academic Clinical Programme, SingHealth Duke-NUS Academic Medical Centre.
The study findings provide a paradigm shift on how to approach the study of other cancers, in addition to liver cancer. Moving forward, the team plans to explore how the epigenome is affected by HCC-related diseases such as Hepatitis B induced HCC and non-viral HCC.
This research comes from one of the largest prospective cohorts for HCC known as the Precision Medicine in Liver Cancer across Asia-Pacific Network (PLANet 1.0) study, which has a cohort of patients from four countries in Asia. The work is also supported by a National Medical Research Council’s Clinician Scientist-Individual Research Grant.
Study reference: Jeon, A.-J., Anene-Nzelu, C. G., Teo, Y.-Y., Lee Chong, S., Sekar, K., Wu, L., Chew, S.-C., Chen, J., Kendarsari, R. I., Lai, H., Ling, W. H., Kaya, N. A., Lim, J. Q., Fui Chung, A. Y., Cheow, P.-C., Kam, J. H., Madhavan, K., Kow, A., Ganpathi, I. S., … Kah-Hoe Chow, P. (2023). A genomic enhancer signature associates with hepatocellular carcinoma prognosis. JHEP Reports. https://doi.org/10.1016/j.jhepr.2023.100715
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
For media enquiries, please contact:
Assistant Manager, Corporate Communications
National Cancer Centre Singapore
Email : firstname.lastname@example.org
About the National Cancer Centre Singapore
The National Cancer Centre Singapore (NCCS) is a leading national and regional tertiary cancer centre with specialists who are experts in treating cancer. NCCS attends to the majority of cancer cases in Singapore’s public healthcare sector. To meet growing healthcare needs, the new NCCS building has increased capacity and expanded facilities dedicated to cancer care, rehabilitation, research and education. NCCS aims to provide our patients with the best outcomes with advanced and innovative treatment such as proton therapy, offered at the new Goh Cheng Liang Proton Therapy Centre.
In addition to offering holistic and multidisciplinary oncology care, our clinicians and scientists collaborate with local and international partners to conduct robust, cutting-edge clinical and translational research. We share our depth of experience and expertise by training local and overseas medical professionals, to support NCCS’ vision to be a global leading cancer centre.
For more information, please visit: www.nccs.com.sg